Want to join the conversation?
$CELG 2Q15 PR: "The Celgene team delivered exceptional results across the portfolio in the second quarter. Continue to invest strategically in the long-term future of Celgene & expect our recently announced transactions with AstraZeneca, Juno and Receptos to accelerate our earnings growth beginning in 2019,” said Bob, CEO.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.